Literature DB >> 25054296

Ask the Experts: How best to treat recurrent glioma.

Victor Alan Levin1.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 25054296      PMCID： PMC6176809          DOI： 10.2217/cns.12.3

Source DB:  PubMed          Journal:  CNS Oncol        ISSN： 2045-0907


× No keyword cloud information.
  14 in total

1.  Combination of 6-thioguanine, procarbazine, lomustine, and hydroxyurea for patients with recurrent malignant gliomas.

Authors:  A P Kyritsis; W K Yung; K A Jaeckle; J Bruner; M J Gleason; S E Ictech; A Flowers; V A Levin
Journal:  Neurosurgery       Date:  1996-11       Impact factor: 4.654

2.  Phase II study of 6-thioguanine, procarbazine, dibromodulcitol, lomustine, and vincristine chemotherapy with radiotherapy for treating malignant glioma in children.

Authors:  V A Levin; K Lamborn; W Wara; R Davis; M Edwards; J Rabbitt; M Malec; M D Prados
Journal:  Neuro Oncol       Date:  2000-01       Impact factor: 12.300

3.  Phase II study of combined carmustine, 5-fluorouracil, hydroxyurea, and 6-mercaptopurine (BFHM) for the treatment of malignant gliomas.

Authors:  V A Levin; S Phuphanich; H C Liu; V Da Silva; J Murovic; A Choucair; M Chamberlain; M Berger; M Seager; R L Davis
Journal:  Cancer Treat Rep       Date:  1986-11

4.  BCNU-5-fluorouracil combination therapy for recurrent malignant brain tumors.

Authors:  V A Levin; W F Hoffman; T L Pischer; M L Seager; E B Boldrey; C B Wilson
Journal:  Cancer Treat Rep       Date:  1978-12

5.  Radiation therapy and hydroxyurea followed by the combination of 6-thioguanine and BCNU for the treatment of primary malignant brain tumors.

Authors:  M D Prados; D A Larson; K Lamborn; M W McDermott; P K Sneed; W M Wara; S M Chang; E E Mack; H G Krouwer; K L Chandler; R E Warnick; R L Davis; J E Rabbitt; M Malec; V A Levin; P H Gutin; T L Phillips; C B Wilson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1998-01-01       Impact factor: 7.038

6.  Investigation of 6-thiodeoxyguanosine alkylation products and their role in the potentiation of BCNU cytotoxicity.

Authors:  W J Bodell
Journal:  IARC Sci Publ       Date:  1986

7.  Potentiation of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced cytotoxicity in 9L cells by pretreatment with 6-thioguanine.

Authors:  W J Bodell; W F Morgan; J Rasmussen; M E Williams; D F Deen
Journal:  Biochem Pharmacol       Date:  1985-02-15       Impact factor: 5.858

8.  13-cis-retinoic acid in the treatment of recurrent glioblastoma multiforme.

Authors:  Siew-Ju See; Victor A Levin; W-K Alfred Yung; Kenneth R Hess; Morris D Groves
Journal:  Neuro Oncol       Date:  2004-07       Impact factor: 12.300

9.  Treatment of recurrent malignant gliomas with high-dose 13-cis-retinoic acid.

Authors:  W K Yung; A P Kyritsis; M J Gleason; V A Levin
Journal:  Clin Cancer Res       Date:  1996-12       Impact factor: 12.531

10.  Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.

Authors:  Kurt A Jaeckle; Kenneth R Hess; W K Alfred Yung; Harry Greenberg; Howard Fine; David Schiff; Ian F Pollack; John Kuhn; Karen Fink; Minesh Mehta; Timothy Cloughesy; M Kelly Nicholas; Susan Chang; Michael Prados
Journal:  J Clin Oncol       Date:  2003-06-15       Impact factor: 44.544
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.